Galectin Q2 net loss $7.6M ($0.12/sh); secures $10M credit line from chairman

GALECTIN THERAPEUTICS INC

2025-Q2 EPS reported -$0.27

Net loss applicable to common stockholders of $7.6M ($0.12 per share) vs $12.4M ($0.20) in Q2 2024.
R&D expenses fell to $3.3M from $9.8M due to NAVIGATE trial completion in Q1 2025.
Cash and equivalents $13.8M at June 30; $10M line of credit from chairman closed July 8.
Company expects sufficient funding to operate through June 30, 2026.
NAVIGATE data at EASL showed belapectin reduced liver stiffness progression over 18 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.